Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301
Retrieved on:
Wednesday, November 15, 2023
Science, Veterinary, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Pandemic, Peptide, MTB, Lung, Safety, Peptidoglycan, The Union, Serum, PGN, Immunoglobulin G, Risk, Gram-positive bacteria, Epitope, Staphylococcus aureus, ELISA, Infection, Staphylococcus, Staphylococcus epidermidis, Vaccine, Mycobacterium tuberculosis, Bacillus subtilis, Cell wall, AMR, Conference, Streptococcus, Virus, Antibody, Bacilli, Mycobacterium smegmatis, Tuberculosis, Public, TB, ICR, Bacteria, Longhorn, MD
Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
Key Points:
- Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
- The data showed that a mycobacterium tuberculosis (MTB) vaccine could generate broader protection against other pathogens susceptible to antimicrobial resistance (AMR).
- LHNVD-301 is an unconjugated, peptide-based vaccine that combines a MTB heat shock protein epitope and a peptidoglycan (PGN) epitope.
- It represents a novel approach that combats AMR, while targeting tuberculosis by combining multiple epitopes specific to MTB and common to gram-positive bacteria into a peptide vaccine.